1. Anuario Estadístico. MINSAP, Cuba. 2007, pp. ¿ 2. National Conprenhensive Cancer Network. Clinical Practice Guidelines V2. 2009. Non Small Cell Lung cancer. 3. Peltz G. Nutrition support in cancer patients: a brief review and suggestion for standard indications criteria. Nutr. J 2002 Sep 30; 1: 1. 4. Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R.Systematic Review of the Treatment of Cancer-Associated Anorexia and Weight Loss J. Clin. Oncol. 2005. 5. Klastersky J, Paesmans M: Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer 34 (Suppl 4): S95-101, 2001. 6. Pignon JP, Stewart LA, Souhami RL, et al.: A meta-analysis using individual patient data from randomised clinical trials (RCTS) of chemotherapy (CT) in non-small cell lung cancer (NSCLC): (2) survival in the locally advanced (LA) setting. Proceedings of the American Society of Clinical Oncology 13: A-1109, 334, 1994. 7. Le Chevalier T, Arriagada R, Quoix E, et al.: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83 (6): 417-23, 1991. 8. Morton RF, Jett JR, McGinnis WL, et al.: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 115 (9): 681-6, 1991. 9. Dillman RO, Seagren SL, Propert KJ, et al.: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323 (14): 940-5, 1990. 10. Schaake-Koning C, van den Bogaert W, Dalesio O, et al.: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (8): 524-30, 1992. 11. Sause WT, Scott C, Taylor S, et al.: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87 (3): 198-205, 1995. . 12. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311 (7010): 899-909, 1995. 13. Langendijk JA, ten Velde GP, Aaronson NK, et al.: Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 47 (1): 149-55, 2000. 14. Komaki R, Cox JD, Hartz AJ, et al.: Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung. Am J Clin Oncol 8 (5): 362-70, 1985. 15. Pfister DG, Johnson DH, Azzoli CG, et al.: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2): 330-53, 2004. 16. Blanke C, Ansari R, Mantravadi R, et al.: Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 13 (6): 1425-9, 1995. 17. Curran WJ, Radiation Therapy Oncology Group: Phase III Randomized Study of Standard Thoracic Irradiation Following VBL/CDDP vs Standard Thoracic Irradiation and Concurrent VBL/CDDP vs Hyperfractionated Thoracic Irradiation and Concurrent VP-16/CDDP for Locally Advanced, Unresectable, non-Small Cell Lung Cancer, RTOG-9410, Clinical trial, Closed. 18. Weick JK, Crowley J, Natale RB, et al.: A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 9 (7): 1157-62, 1991 19. O'Connell JP, Kris MG, Gralla RJ, et al.: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4 (11): 1604-14, 1986 20. Le Chevalier T, Brisgand D, Douillard JY, et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (2): 360-7, 1994. 21. Johnson DH, Paul DM, Hande KR, et al.: Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 14 (7): 2054-60, 1996. 22. Bonomi P, Kim K, Fairclough D, et al.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18 (3): 623-31, 2000. 23. Hotta K, Matsuo K, Ueoka H, et al.: Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15 (12): 1782-9, 2004. 24. Langer CJ, Manola J, Bernardo P, et al.: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 (3): 173-81, 2002. 25. Perrone F, Gallo C, Gridelli C: Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 (13): 1029-30; discussion 1030-1, 2002. 26. Gridelli C, Perrone F, Gallo C, et al.: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (5): 362-72, 2003. 27. Hensing TA, Peterman AH, Schell MJ, et al.: The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98 (4): 779-88, 2003. 28. Maestu I, Gómez-Aldaraví L, Torregrosa MD, et al.: Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42 (3): 345-54, 2003. 29. Schiller JH, Harrington D, Belani CP, et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2): 92-8, 2002. 30. Kelly K, Crowley J, Bunn PA Jr, et al.: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 (13): 3210-8, 2001. 31. Miller JI Jr, Phillips TW: Neodymium:YAG laser and brachytherapy in the management of inoperable bronchogenic carcinoma. Ann Thorac Surg 50 (2): 190-5; discussion 195-6, 1990. 32. Mandell L, Hilaris B, Sullivan M, et al.: The treatment of single brain metastasis from non-oat cell lung carcinoma. Surgery and radiation versus radiation therapy alone. Cancer 58 (3): 641-9, 1986. 33. DeAngelis LM, Mandell LR, Thaler HT, et al.: The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 24 (6): 798-805, 1989 34. Macbeth F, Toy E, Coles B, et al.: Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev (3): CD002143, 2001. 35. Brown J,Byers T,Doyle C et al .Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices CA Cancer J Clin. 2003;53(5):268-91. 36. Meldrum M. The ladder and the clock: cancer pain and public policy at the end of the twentieth century. J Pain Symptom Manage 2005; 29(1):41-54. 37. World Health Organization. Cancer Pain Relief. Geneve. Anesthesia & Analgesia 1986 67, 9, 115- 11 6. 38. Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, De Conno F; The Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002; 94 (3):832-9. 39. Toffoli G. Pharmacology of Epidermal Growth Factor Inhibitors. The Int. J. Biol. Markers. 2007, 22 (1) S.4, pp. S24- S39. 40. Hirsch F, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003, 21:3798-3807. 41. Cavalli, F.; Hansen, H. H.; Kaye, S. B. Textbook in Medical Oncology; Third edition. Taylor & Francis Ed., London and New York, 2004. 42. González G, Lage A. Cancer Vaccines for Hormone / Growth Factor Immune Deprivation: A Feasible Approach for Cancer Treatment. Current Cancer Drug Targets. 2007 (7) 191-201. 43. [5] Macías, A.; Azavedo, E.; Hagerstrom, T.; Klintenberg, C.; Pérez, R.; Skoog, L. Prognostic significance of the receptor for epidermal growth factor in human mammary carcinoma. Anticancer Res. 1987, 7, 459-464. 44. [6] Arteaga, C.L. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res. 2003, 284:122-130. 45. [7] Lage, A., Crombet, T., and Gonzalez, G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med. 2003, 35:327-336. 46. [8] Perez, R., Pascual, M., Macias, A., and Lage, A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat. 1984, 4:189-193. 47. [9] Gonzalez G, Sanchez B, Suarez E, Beausoleil I, Perez O, LastreM, et al. Induction of immune recognition of self-epidermal growth factor (EGF): effect on EGF biodistribution and tumor growth. Vac Res. 1996, 5(4):233–44. 48. [10] Gonzalez G, Pardo OL, Sanchez B, Garcia JL, Beausoleil I, Marinello P, et al. Induction of immune recognition of self-epidermal growth factor II: characterization of the antibody immune response and the use of a fusion protein. Vac Res. 1997, 6(2):91–100. 49. [11] Gonzalez G, Crombet T, Catala M, Mirabal V, Hernandez JC, Gonzalez Y, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998; 9(4):431–5. 50. [12] Hirsch FR.,. Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K,et al. Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. J Clin Oncol. 2008, 26:3351-3357. 51. Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003;14(3):461-6. 52. Gonzalez, G., Crombet, T., Neninger, E., Viada, C., and Lage, A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin. 2007, 3: 8-13. 53. Neninger E., García B., Crombet T., Viada C., Pereda S., Leonard I., Mazorra Z., Fleites G., González M., Wilkinson B., González G., Lage A. Combining an EGF-based cancer vaccine with chemotherapy In advanced non small cell lung cancer. JIT 2008 (Submitted). 54. Montero E., Gonzalez, Avellanet J., Valdes M., Lopez A., Perez R. and Lage A. Transient B-cell depletion boosts antibody-forming cells expansion driven by an Epidermal Growth Factor-based cancer vaccine. Vaccine 2008 (Submitted). 55. Neninger E., de la Torre A., Osorio M. Catalá M., Bravo I., Mendoza M., Abreu A., Acosta S., Rives R., del Castillo C., González M., Viada C., GarcÍa B., Crombet T., González G., Lage A. Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced NSCLC. JCO 2008 26(9) 1462-68. 56. García B., Neninger E., de la Torre A., Leonard I., Martínez R., Viada C., González G., Mazorra Z., Lage A., Crombet T. Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti-Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non Small-Cell Lung Cancer PatientsTreated with the Epidermal Growth Factor Cancer Vaccine. Clin Cancer Res 2008; 14(3) February 1. 57. 58. [16] Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., and Martin, F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34:336-344. 59. [17] Man, S., Bocci, G., Francia, G., Green, S.K., Jothy, S., Hanahan, D., Bohlen, P., Hicklin, D.J., Bergers, G., and Kerbel, R.S. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002, 62:2731-2735. 60. [18] Terando, A., and Mule, J.J. On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother 2003, 52:680-685. 61. [19] Ehrke, M.J. Immunomodulation in cancer therapeutics. Int Immuno pharmacol 2003, 3:1105-1119. 62. Cupps, T.R., Edgar, L.C., and Fauci, A.S. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol. 1982, 128:2453-2457. 50. 63. Sinkovics, J.G., and Horvath, J.C. Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol. 2006, 29:765-777. 64. Crombet T., Neninger E., Catalá M., García B., Leonard I., Martínez L., González G., Pérez R., Lage A. Treatment of NSCLC Patients with an EGF-Based Cancer Vaccine. Cancer Biology & Therapy 2006, 5:2, 145-149. 65. Berd D, Sato T,Maguire Jr HC, Kairys J, Mastrangelo MJ. Immunopharma-cologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22(3):403–15. 66. Gardiner DF, Huang Y, Basu S, Leung L, Song Y, Chen Z, et al. Multiple-site DNA vaccination enhances immune responses in mice. Vaccine 2006;24(3):287–92. 67. Nicholson KG, Prestage H, Cole PJ, Turner GS, Bauer SP. Multisite intradermal antirabies vaccination. Immune responses in man and protection of rabbits against death from street virus by postexposure administration of humandiploid- cell- strain rabies vaccine. Lancet 1981;2(8252):915–8. 68. Khawplod P, Wilde H, Tepsumethanon S, Limusanno S, Tantawichien T, Chomchey P, et al. Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin. Clin Infect Dis 2002;35(12):1562–5. 69. Warrell MJ, Suntharasamai P, Nicholson KG, Warrell DA, Chanthavanich P, Viravan C, et al. Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens. Lancet 1984;1(8382):874–6. 70. Dennehy M, Williamson AL. Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 2005; 23 (10):1209–24. 71. Jansen T, Hofmans MP, Theelen MJ, Manders FG, Schijns VE. Dose and timing requirements for immunogenicity of viral poultry vaccine antigen: investigations of emulsion-based depot function. Avian Pathol 2007;36(5):361–5. 72. Aucouturier J, Ascarateil S, Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006; 24 Suppl 2:S2-44–5. 73. Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 2008;111(6):3116–25. 74. Lage A, Perez R, Fernandez LE. Therapeutic cancer vaccines: at midway between immunology and pharmacology. Curr Cancer Drug Targets 2005; 5(8):611–27. 75. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997;156:199- 209. 76. Friedman A, Cohen IR. T cell Ir phenotype modified by excising primary antigen deposit. Immunogenetics 1984;19(5):449–54. 77. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001;293(5528):251–3. 78. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med 1998; 339(26):1905–13. 79. Couch M, Saunders JK, O’Malley Jr BW, Pardoll D, Jaffee E. Spatial distribution of tumor vaccine improves efficacy. Laryngoscope 2003; 113 (8):1401–5. 80. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 2008; 105(5):1650–5 81. Rodriguez PC., Gonzalez I., Gonzalez A., Avellanet J., Lopez A., Perez R., Lage A., and Montero E. Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine. Vaccine 2008, 26:4647-4654. 82. Hanahan D & Weinberg RA. The Hallmarks of cancer. Cell 2000 100. 57-70. 83. Dunn GP., Old LJ., Schreiber RD. The Three Es of Cancer Immunoediting. Annu. Rev. Immunol. 2004, 22:329-60. 84. Guido Kroemer and Jacques Pouyssegur. Tumor Cell Metabolism: Cancer’s Achilles’ Heel. Cancer Cell 2008 (13) June. 472-81. 85. Finn, O.J. Cancer immunology. N Engl J Med. 2008, 358:2704-2715. 86. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 87. Finn, O.J. Tumor immunology top 10 list. Immunol Rev. 2008, 222:5-8. 88. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with citotoxic chemotherapy. Cancer Res. 2005, 65:8059- 8064. 89. Coles, A.J., Wing, M., Smith, S., Coraddu, F., Greer, S., Taylor, C., Weetman, A., Hale, G., Chatterjee, V.K., Waldmann, H., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999, 354:1691-1695. 90. Dass, S., Vital, E.M., and Emery, P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007, 56:2715-2718. 91. Goetz, M., Atreya, R., Ghalibafian, M., Galle, P.R., and Neurath, M.F. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007, 13:1365-1368.